Beta 2-adrenoceptor-mediated positive inotropic effect of adrenaline in human ventricular myocardium. Quantitative discrepancies with binding and adenylate cyclase stimulation.
Experiments were designed to unravel the relative contribution of beta 1- and beta 2-adrenoceptors to the positive inotropic effects of adrenaline and noradrenaline in isolated tissues of left ventricular myocardium of man. We also analyzed relationships between the fractions of human left ventricular beta 1- and beta 2-adrenoceptors, estimated from binding assays, and stimulation of adenylate cyclase and contractile force by adrenaline and noradrenaline. Selective blockade of beta 2-adrenoceptors by erythro-(+/-)-(alpha-methyl-indan-4-yloxy)-3-isopropylaminobuta n-2-ol (ICI 118,551) attenuated the increase of contractile force caused by adrenaline but not by noradrenaline, suggesting some involvement of beta 2-adrenoceptors. Selective blockade of beta 2-adrenoceptors without affecting beta 1-adrenoceptors still enabled both adrenaline and noradrenaline to cause maximum possible increases of contractile force through beta 1-adrenoceptors. A direct involvement of beta 2-adrenoceptors became manifest by selectively antagonizing beta 1-adrenoceptors by 1-[2[3-carbamoyl-4-hydroxy)phenoxy)ethylamino]- 3-[4(1-methyl-4-trifluoromethyl-2-imidazolyl)phenoxy]-2-propanol (CGP 20712 A) without affecting beta 2-adrenoceptor. beta 2-adrenoceptors can mediate half of the maximum increase of contractile force elicited by low concentrations of adrenaline and also contribute to the increase of contractile force caused by high concentrations of noradrenaline. beta-adrenoceptors were labelled in membrane particles with 3H-(-)-bupranolol in the absence (beta 1 & beta 2) and presence of 500 nmol/l CGP 20712 A (beta 2). 71% of the beta-adrenoceptors were beta 1 and 29% beta 2. Binding inhibition experiments with CGP 20712 A and ICI 118,551 yielded 74% beta 1 and 26% beta 2.(ABSTRACT TRUNCATED AT 250 WORDS)
D000262:Adenylyl Cyclases / Q000378:metabolism*; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D004837:Epinephrine / Q000494:pharmacology*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D066298:In Vitro Techniques; D009200:Myocardial Contraction / Q000187:drug effects*; D009206:Myocardium / Q000201:enzymology / Q000378:metabolism; D009638:Norepinephrine / Q000494:pharmacology; D011412:Propanolamines / Q000494:pharmacology; D011943:Receptors, Adrenergic, beta / Q000187:drug effects* / Q000378:metabolism; D014665:Vasodilator Agents / Q000494:pharmacology
D000319:Adrenergic beta-Antagonists; D007093:Imidazoles; D011412:Propanolamines; D011943:Receptors, Adrenergic, beta; D014665:Vasodilator Agents; C026777:ICI 118551; C049763:CGP 20712A; D000262:Adenylyl Cyclases; D009638:Norepinephrine; D004837:Epinephrine